Home | Sitemap | Search | Contact A- A A+
   
English
 
    Public Member Support us  
 
About IBCSG
Patients & Public
IBCSG Clinical Trials
Open Trials
IBCSG 22-00
IBCSG 23-01
IBCSG 24-02
IBCSG 25-02
IBCSG 27-02
IBCSG 34-05
IBCSG 35-07
IBCSG 36-07
IBCSG 37-07
Breast Cancer Stages
Breast Cancer Background
Health Professionals
Tissue Bank / Translational Research
Home > Public > Patients & Public > IBCSG Clinical Trials > Open Trials > IBCSG 24-02

IBCSG 24-02 / BIG 2-02 (SOFT) 

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer

Suppression of Ovarian Function Trial (SOFT)

DESIGN

Please click on the picture to see a larger version

Co-SOFT Substudy

The Cognitive Function Substudy is investigating cognitive function for patients participating in the SOFT trial in selected centers.
Study Chairs
BIG: Dr. Prue Francis - Melbourne, Australia
US Intergroup: Dr. Gini Fleming - Chicago, USA

Statistician
Dr. Meredith Regan

Trial Coordinators
Karolyn Scott, Jocelyn Swick, Kris Rickard, Tara Scolese
IBCSG Data Management Center/FSTRF 4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg24-26_STP@fstrf.org

Date of Activation
August 4, 2003

Targeted Accrual
3000 patients
Substudies Co-SOFT Substudy
Results Publications Results & Publications
Other Pathology

News

11.12.2008:
BIG 1-98: Results from sequential treatment analysis and updated monotherapy analysis

11.12.2008:
Brinker Award for Richard Gelber and Aron Goldhirsch

11.12.2008:
All presentations from investigators' meetings at San Antonio Breast Cancer Symposium now

All News

  
  Print
Disclaimer | Copyright